Myles Wolf
CIK: 0001808317
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AKBA
Akebia Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
About Wolf Myles
Wolf Myles (SEC CIK 0001808317) files insider reports with the SEC as Director of Akebia Therapeutics, Inc. (AKBA).
Signal8 holds 2 ownership filings by Wolf Myles, all Form 4s, filed between Jun 11, 2025 and Jun 22, 2026. Those filings report 2 transactions, from Jun 10, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Wolf Myles's filings is in CAMBRIDGE, MA.
Recent filings by Wolf Myles
Other insiders filing for Akebia Therapeutics, Inc. (AKBA)
- Butler John P., CEO and President
- Ostrowski Erik, SVP, CFO, CBO & Treasurer
- Smith Cynthia, Director
- ROGERS MICHAEL W, Director
- FRIESON RON, Director
- ZUMWALT LEANNE M, Director